广东粤运交通拯救有限公司
SG胜游医疗科学有限公司 (MicroPort Scientific Corporation) is a Hong Kong-listed multinational medical device conglomerate developing high-end interventional and implantable devices across cardiovascular, neurovascular, electrophysiology, surgical robotics, and orthopedics, serving 20,000+ hospitals across 100+ countries through a multi-subsidiary structure and dual domestic-international distribution network.
- Company typePublic
- Founded1998
- HeadquartersShanghai, China
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What 广东粤运交通拯救有限公司 does
SG胜游医疗科学有限公司 (MicroPort Scientific Corporation) is a Hong Kong-listed (00853.HK) multinational high-end medical device conglomerate founded in 1998 in Shanghai Zhangjiang Science City. The company develops, manufactures, and commercializes interventional and implantable medical devices across 12 major business clusters covering cardiovascular and structural heart disease, cerebrovascular and neurological modulation, peripheral vascular and life-support systems, electrophysiology and cardiac rhythm management, medical AI and robotics, orthopedics and sports medicine, urology and digestive diseases, ophthalmology, endocrinology and reproduction, aesthetic and skincare, and regenerative medicine. Flagship products include the Firehawk® coronary drug-eluting stent (lowest drug dose globally, Lancet-published TARGET AC data), VitaFlow® transcatheter aortic valve system, Columbus® 3D cardiac electrophysiology mapping system, Toumai® laparoscopic surgery robot, SkyWalker® orthopedic surgical robot, R-one® vascular interventional robot, NUMEN® and Tubridge® neurovascular devices, plus a broad portfolio of pacemakers, ICDs, cryoablation systems, and peripheral vascular products. The company holds nearly 12,000 patents globally and has received 5 National Science and Technology Progress Awards.
The company operates through a multi-subsidiary structure with 20+ entities across 12 business clusters, of which five are independently publicly listed (688016.SH, 02160.HK, 02172.HK, 688351.SH, 02252.HK). Distribution is executed through a dual domestic-overseas network: 微联微通 (Weilian Weitong) handles Chinese primary healthcare institution coverage across 100+ cities and all provinces, while 全球通 (Global通) extends reach to 100+ countries and 20,000+ hospitals internationally. The company runs an integrated innovation-to-commercialization pipeline including the 知行学院 (Innovation & Initiation Institute) physician training platform, 良知创意中心 (Creative Conscience Center) doctor-industry collaboration program, 奇迹点® (MiraclePoint) startup incubator, and 良知关爱 patient education center. Products are evenly distributed across Asia-Pacific, Europe, and the Americas, with manufacturing and R&D sites in China (Shanghai, Suzhou, Jiaxing), the United States (Irvine, Memphis), France (Clamart), Italy (Saluggia), Germany (Aachen), the UK (Oxford), and the Dominican Republic.
Revenue is generated through B2B sales of high-end medical devices and disposables to hospitals under procurement and reimbursement frameworks, supplemented by clinical training services, spare parts, and consumables. FY2022 revenue was USD 840.8 million (approximately HKD 6.6 billion) with gross profit of USD 501.8 million and R&D spending of USD 419.8 million (~50% of revenue), reflecting a capital-intensive reinvestment model. The customer base is highly diversified across 20,000+ healthcare institutions, with no single customer concentration risk observable in the dataset.
广东粤运交通拯救有限公司 firmographics
Firmographics- Name
- 广东粤运交通拯救有限公司
- Legal name
- MicroPort Scientific Corporation Limited (SG胜游医疗科学有限公司)
- Website
- https://yyjtzj.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Short description
- SG胜游医疗科学有限公司 (MicroPort Scientific Corporation) is a Hong Kong-listed multinational medical device conglomerate developing high-end interventional and implantable devices across cardiovascular, neurovascular, electrophysiology, surgical robotics, and orthopedics, serving 20,000+ hospitals across 100+ countries through a multi-subsidiary structure and dual domestic-international distribution network.
- Ownership category
- akta.pro rank
广东粤运交通拯救有限公司 industry classification
Industry- Product category
- Interventional Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
Keywords
Where 广东粤运交通拯救有限公司 is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices13 records
Markets served
广东粤运交通拯救有限公司 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Product Sales: SG胜游 generates revenue primarily through the sale of proprietary high-end medical devices across 12 major business clusters covering cardiovascular, neurovascular, peripheral vascular, electrophysiology, robotics, orthopedics, urology, gynecology, ophthalmology, and aesthetics. Products are sold directly to hospitals and through distributor networks.
- Aftermarket Services and Training: Revenue from clinical training services through 知行学院 (Innovation & Initiation Institute), spare parts, and consumables for deployed medical devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B hospital procurement model - no public consumer pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
广东粤运交通拯救有限公司 product offering
Product offeringCore offering
The company distributes and sells a comprehensive portfolio of high-end interventional and implantable medical devices, including coronary drug-eluting stents, transcatheter aortic valve systems, neurovascular embolization coils and flow diverters, aortic stent grafts, peripheral vascular devices, electrophysiology mapping and ablation systems, implantable pacemakers and defibrillators, ECMO and life-support systems, and surgical/orthopedic robotics. The website lists hundreds of named SKUs spanning 12 medical device business clusters, with named products including Firehawk®, VitaFlow Liberty®, Columbus®, Toumai®, SkyWalker®, Castor®, and Tubridge®. The site also operates an innovation incubator (奇迹点®), a physician training academy (创新知行学院), a doctor-industry collaboration center (良知创意中心), and a patient education center (良知关爱).
Product overview
SG胜游®集团 is a diversified, globally-operating high-tech medical device conglomerate with a portfolio spanning 12 major business clusters: cardiovascular and structural heart disease, cerebrovascular and neurological modulation, peripheral vascular and life-support systems, electrophysiology and cardiac rhythm management, medical AI and robotics, orthopedics and sports medicine, urology and digestive diseases, ophthalmology and respiratory care, cancer treatment and life保障, endocrine diagnostics and reproduction, synthetic biology and regenerative medicine, and aesthetic and functional skincare. The group operates multiple listed subsidiaries (MicroPort CardioFlow, MicroPort NeuroTech, MicroPort MedBot, MicroPort EP MedTech, Shanghai MicroPort Endovastec) and offers hundreds of medical solutions covering cardiac stents, TAVR systems, electrophysiology mapping and ablation, pacemakers, surgical robots, orthopedic implants, cryoablation, insulin pumps, IVF products, and skincare. Its products are deployed in over 20,000 hospitals across 100+ countries, with a new product launched approximately every 5 seconds globally.
Differentiator
Problem solved
Functional benefit
Brands
- 心脉医疗: Endovascular stent grafts and large vessel diseases subsidiary, publicly listed on Shanghai STAR Market (688016.SH)
- 心通医疗
- SG胜游脑科学
- SG胜游电生理
- SG胜游机器人 / MicroPort MedBot
- 微联微通
- 奇迹点孵化器Plus
- 良知关爱
- 创新知行学院
- 良知创意中心
- 创领心律医疗
- CRM (MicroPort Cardiac Rhythm Management)
- MicroPort Orthopedics
Products and services
- Intravascular Imaging and Diagnostic Systems (Decypher™ IVUS, ArgusClarity® OCT, PICCO hemodynamic monitor)
- Urology and Gynecology Devices (EZ-UroGuide®, EZ-Captcher® stone baskets, Lotus™ assisted reproduction)
- Insulin Pump and Endocrine Devices (La Fenice® / 火凤凰® insulin pump, Ticker™ AI box)
- Tumor Cryoablation and Aesthetic Product Lines (TACTIC™ tumor cryoablation, REVEDA® functional skincare)
- Coronary Drug-Eluting Stent Systems (Firehawk®, Firebird2®, FireKingFisher®, Firecondor®, Firesorb®, Firelimus®, Firebird Pro+®)
- Transcatheter Aortic Valve Systems (VitaFlow®, VitaFlow Liberty®, Alwide®Plus, AnchorMan®)
- Neurovascular Devices (NUMEN® embolization coils, Tubridge® flow diverter, NeuroHawk®, Tigertriever®, WILLIS®, Bridge® vertebral stent, APOLLO™)
- Aortic Stent Grafts (Castor®, Hercules® Low Profile, Talos®, Aegis®, Minos®, Fontus®, CRONUS®)
- Peripheral Vascular Devices (Reewarm®, Ryflumen®, Vflower® venous stent, Fishhawk®, L-REBOA®, Vewatch® IVC filter, VEPACK®)
- Electrophysiology Systems (Columbus® 3D mapping, FireMagic® ablation, IceMagic® cryoablation, OptimAblate®, EasyFinder®, EasyLoop®, PathBuilder®, magnetic navigation Niobe®)
- Implantable Pacemakers and ICDs (Rega®, Trefle®, Orchidee®, ESPRIT, Reply, ENO, Beflex, Vega, Bonafire, Platinium™)
- ECMO and Cardiopulmonary Bypass Systems (VitaSprings® membrane oxygenator, Pump N'Run® centrifugal pump, SleekFlow® cannulae, Infinity115™ system)
- Surgical and Orthopedic Robotic Systems (Toumai® laparoscopic robot, SkyWalker® orthopedic navigation, R-one® vascular robot, DFVision® 3D endoscope, iSR'obot® Mona Lisa prostate biopsy robot)
- Structural Heart and Congenital Heart Occluders (Evermend® 怡心® ASD/VSD/PDA occluders, AnchorMan® left atrial appendage occluder, THUNDERBIRD® hernia patch)
Quantifiable outcome
- Firehawk® stent uses only 1/3 of the drug dose of competitors while maintaining equivalent safety and efficacy (TARGET AC 5-year follow-up, zero stent thrombosis rate; Lancet publication)
- +5 more outcomes
Companies that use 广东粤运交通拯救有限公司
Customer profileNamed customers6 records
Segments7 records
Ideal customer profiles1 record
广东粤运交通拯救有限公司 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
广东粤运交通拯救有限公司 partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- Hemovent (Germany)minorHemovent's MOBYO™ membrane lung obtained EU approval; SG胜游 holds strategic investment in Hemovent.
- NDR (Singapore percutaneous navigation robot company)minorSG胜游 entered strategic investment agreement and joint venture agreement with Singapore-based NDR for percutaneous navigation robot technology in China.
- Robocath (France vascular interventional robot company)minorSG胜游 entered strategic investment agreement and joint venture agreement with France-based Robocath for vascular interventional robotics in China.
- Siemens Healthineers (西门子医疗)coreSG胜游 entered strategic cooperation with Siemens Healthineers covering medical angiography X-ray systems.
- Purple Medical (India)minorSG胜游 made strategic investment in India-based Purple Medical and established a joint venture company.
- 4C Medical (US)minor心通医疗 invested in 4C Medical (US) and its AltaValve™ product received FDA breakthrough device designation for two treatment indications.
- LivaNova (UK/Sorin)coreSG胜游 acquired LivaNova's cardiac rhythm management business for approximately USD 190 million cash, establishing CRM global headquarters in Paris.
Scale indicators8 records
Recent moves6 records
Expansion highlights10 records
广东粤运交通拯救有限公司 competitors and assessment
Company assessmentDirect peers
- Medtronic: Global leader in cardiovascular, structural heart, CRM, neurovascular, and surgical devices — direct peer across nearly every MicroPort franchise at scale, and the most established incumbent MicroPort competes against in US/EU and China.
- Boston Scientific: Direct competitor in coronary stents, peripheral vascular, electrophysiology (mapping/ablation), and structural heart — closely comparable product portfolio and global distribution footprint.
- Edwards Lifesciences: Pure-play TAVR leader (Sapien platform) and structural heart incumbent. The closest head-to-head competitor to MicroPort's VitaFlow TAVR franchise, including in EU and emerging markets.
- Abbott Laboratories: Major peer across coronary stents (Xience), structural heart (Portico), CRM (pacemakers/ICDs), and neurovascular — comparable in cardiovascular breadth and global footprint.
- Stryker: Direct peer in orthopedics (knee/hip implants, MAKO robotics) — competes against MicroPort Orthopedics in both reconstructive implants and robotic surgical navigation.
- Intuitive Surgical: Global leader in surgical robotics (da Vinci); competes directly with MicroPort MedBot's Toumai laparoscopic platform in China and selected international markets.
- Penumbra: Specialist in neurovascular thrombectomy and peripheral vascular — competes with MicroPort NeuroTech (Tigertriever, WAVE-track) and Fishhawk peripheral thrombectomy products.
- Zimmer Biomet: Global orthopedic reconstructive implant leader — comparable peer to MicroPort Orthopedics in knee/hip replacement and adjacent robotic navigation.
Emerging players
- Robocath: France-based vascular interventional robotics company in which MicroPort has strategic investment and a China JV — adjacent emerging player in robotic PCI where MicroPort is building presence via R-one.
- Shockwave Medical: Intravascular lithotripsy leader in coronary and peripheral vascular — emerging peer to MicroPort's Firehawk, TomaHawk shock wave, and peripheral vascular franchises in the same call points.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
广东粤运交通拯救有限公司 compliance and trust
Trust signalCompliance2 records
广东粤运交通拯救有限公司 financial estimates
Financial estimateRevenue estimate
Valuation estimate
广东粤运交通拯救有限公司 leadership team
Management profileNumber of profiles
Profiles1 record
广东粤运交通拯救有限公司 subsidiaries and ownership
Company hierarchySubsidiaries17 records
广东粤运交通拯救有限公司 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
广东粤运交通拯救有限公司 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 广东粤运交通拯救有限公司
What does 广东粤运交通拯救有限公司 do?
The company distributes and sells a comprehensive portfolio of high-end interventional and implantable medical devices, including coronary drug-eluting stents, transcatheter aortic valve systems, neurovascular embolization coils and flow diverters, aortic stent grafts, peripheral vascular devices, electrophysiology mapping and ablation systems, implantable pacemakers and defibrillators, ECMO and life-support systems, and surgical/orthopedic robotics. The website lists hundreds of named SKUs spanning 12 medical device business clusters, with named products including Firehawk®, VitaFlow Liberty®, Columbus®, Toumai®, SkyWalker®, Castor®, and Tubridge®. The site also operates an innovation incubator (奇迹点®), a physician training academy (创新知行学院), a doctor-industry collaboration center (良知创意中心), and a patient education center (良知关爱).
Is 广东粤运交通拯救有限公司 a public or private company?
广东粤运交通拯救有限公司 is a public company. It is classified as public and is currently operating.
When was 广东粤运交通拯救有限公司 founded?
广东粤运交通拯救有限公司 was founded in 1998.
Where is 广东粤运交通拯救有限公司 based?
广东粤运交通拯救有限公司 is headquartered in Shanghai, China, in the Asia region.
How does 广东粤运交通拯救有限公司 make money?
Two revenue lines are on record. Medical Device Product Sales are the primary driver. The others are aftermarket Services and Training.
Who are 广东粤运交通拯救有限公司's main competitors?
Direct peers on record are Medtronic, Boston Scientific, Edwards Lifesciences, Abbott Laboratories, Stryker, Intuitive Surgical, Penumbra and Zimmer Biomet. Emerging players are Robocath and Shockwave Medical.
Does 广东粤运交通拯救有限公司 have an API?
No public API is recorded for 广东粤运交通拯救有限公司.
What industry is 广东粤运交通拯救有限公司 in?
广东粤运交通拯救有限公司's product category is Interventional Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 334510 and its SIC code is 3841.